Daqin Pharmaceuticals-B (06996.HK) received a first payment of $60 million from UCB for ATG-201.

China Fortune Financial News App, Decchi Pharmaceuticals-B (06996.HK) announced that the company (as licensor) has entered into a global exclusive licensing agreement with UCB (UCB) (as licensee) for the CD19/CD3 bispecific T cell engager (TCE) antibody ATG-201. This group has received an initial payment of 60 million US dollars from UCB. The receipt of this milestone payment under the agreement with UCB further strengthens the group's cash position, providing strong financial support for advancing the group's innovative drug pipeline and accelerating the benefit to more patients.